cell therapies are flop in the making

Discussion in 'Bristol-Myers Squibb' started by anonymous, Aug 21, 2020 at 2:28 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Listening difficult for you?

    He said THIS YEAR or NEXT YEAR. And he is talking about LAUNCH not approval. If approved in Nov, it's extremely unlikely would launch before Jan 1.
     

  2. anonymous

    anonymous Guest

    Why wouldn’t there be enough time if FDA inspects facilities by end of month as expected?
     
  3. anonymous

    anonymous Guest

    When you say "as expected" do you mean internally or publicly? Because publicly the company has not said if or when inspections are scheduled.
     
  4. anonymous

    anonymous Guest

    That’s not true. FDA hasn’t scheduled any of the inspections yet and aren’t expected to any time soon. There is large backlog that FDA is working through so our guys will have to be patient. We are ready to go when the FDA shows up.
     
  5. anonymous

    anonymous Guest

    Yes, you can sell it by calling it in. Probably makes sense given that milestones may be missed. $2 is better than $0.
     
  6. anonymous

    anonymous Guest

    we dont know it will be $0. could also be $9. my guess is that inspections will be delayed but it wont impact CVR.
     
  7. anonymous

    anonymous Guest

    Told you! This company blows...
     
  8. anonymous

    anonymous Guest

    Well, technically, it’s smart for us because we don’t have to payout the Celgene shareholders
     
  9. anonymous

    anonymous Guest

    I don’t follow but it may be because I’m out of the loop. Care to explain what you are you referring to?
     
  10. anonymous

    anonymous Guest

    Ahhh, I see now that liso-cel was postpone
     
  11. anonymous

    anonymous Guest

    Does anyone know if we are allowed to buy the CVR or is that not allowed?